Melane Sampson, Author at BioTuesdays

Markets

Stifel starts GH Research at buy; PT $26

Stifel launched coverage of GH Research PLC (NASDAQ:GHRS) with a “buy” rating and price target of $26. The stock closed at $17.25 on July 19. “We believe GH offers an attractive way to invest in the psychedelics space...

July 20, 2021

Developments

Cognetivity ICA test to be deployed in new NHS brain clinic in UK

Cognetivity Neurosciences’ (CSE:CGN; OTCQB:CGNSF) Integrated Cognitive Assessment (ICA) test is to form an integral part of a new and highly innovative clinic in the UK’s National Health Service (NHS) dedicated to...

July 15, 2021

Developments

ENA Respiratory begins Phase 1 study of COVID-19 preventative nasal spray

Closely held ENA Respiratory of Australia initiated a Phase 1 human safety study of INNA-051, being developed to activate innate immunity in the nose, the primary entry portal of most respiratory viral infections. A...

July 14, 2021

Developments

Hepion posts positive Phase 2a NASH data in AMBITION trial

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that all primary endpoints were met in its Phase 2a AMBITION clinical trial in patients with non-alcoholic steatohepatitis (NASH). The Phase 2a trial was designed to...

July 13, 2021

Developments

Advaxis and Biosight in merger pact

Advaxis (NASDAQ:ADXS) and closely held Biosight of Israel entered into a definitive merger agreement, with shareholders of Biosight becoming the majority holders of the combined company. Advaxis will be renamed Biosight...

July 7, 2021

Executive Moves

Q32 Bio names Adam Cutler as CFO

Adam Cutler Closely-held Q32 Bio appointed Adam Cutler as chief financial officer, with responsibility for all aspects of its financial strategy and operations. Mr. Cutler has more than 20 years of experience in...

July 7, 2021

Developments

UNITY Biotech posts positive Phase 1 data in advanced vascular eye disease

UNITY Biotechnology (NASDAQ:UBX) announced positive data from its Phase 1 safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet age-related macular degeneration (AMD) for...

July 6, 2021

Developments

Titan posts positive results in first studies of TP-2021 implant in chronic pruritus

Titan Pharmaceuticals (NASDAQ:TTNP) reported that an in vivo study of its ProNeura-based human kappa-opioid receptor agonist, TP-2021, implant in an established itch-induced mouse model has demonstrated the...

June 23, 2021

Executive Moves

Talkiatry names Jared Camins as CTO

Closely held Talkiatry, a leading mental health care provider that connects people with high-quality psychiatric care via telehealth or in-person, appointed Jared Camins as chief technology officer.

June 22, 2021

Developments

Profound’s TULSA-PRO posts better safety, equal efficacy in real-world analysis of prostate cancer partial ablation, BPH

A peer-reviewed paper authored by clinicians and researchers from Germany’s ALTA Klinik and the University Hospital, LMU Munich, and published in Urologic Oncology illustrates that Profound Medical’s...

June 21, 2021

Author - Melane Sampson

Stifel starts GH Research at buy; PT $26

Cognetivity ICA test to be deployed in new NHS brain clinic in UK

ENA Respiratory begins Phase 1 study of COVID-19 preventative nasal spray

Hepion posts positive Phase 2a NASH data in AMBITION trial

Advaxis and Biosight in merger pact

Q32 Bio names Adam Cutler as CFO

UNITY Biotech posts positive Phase 1 data in advanced vascular eye disease

Titan posts positive results in first studies of TP-2021 implant in chronic pruritus

Talkiatry names Jared Camins as CTO

Profound’s TULSA-PRO posts better safety, equal efficacy in real-world analysis of prostate cancer partial ablation, BPH

Subscribe